Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer.
Zalazar F, Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, Siervi A. Zalazar F, et al. Among authors: spallanzani rg. Curr Pharm Biotechnol. 2019;20(12):1072. doi: 10.2174/138920102012190919103433. Curr Pharm Biotechnol. 2019. PMID: 31701844
By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Curr. Pharm. ...
By: Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Sie …
Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.
Zalazar F, De Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, De Siervi A. Zalazar F, et al. Among authors: spallanzani rg. Curr Pharm Biotechnol. 2015;16(6):553-63. doi: 10.2174/138920101606150407114407. Curr Pharm Biotechnol. 2015. Retraction in: Curr Pharm Biotechnol. 2019;20(12):1072. doi: 10.2174/138920102012190919103433 PMID: 25860066 Retracted.
Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.
Spallanzani RG, Dalotto-Moreno T, Raffo Iraolagoitia XL, Ziblat A, Domaica CI, Avila DE, Rossi LE, Fuertes MB, Battistone MA, Rabinovich GA, Salatino M, Zwirner NW. Spallanzani RG, et al. Cancer Immunol Immunother. 2013 Dec;62(12):1781-95. doi: 10.1007/s00262-013-1483-x. Epub 2013 Oct 11. Cancer Immunol Immunother. 2013. PMID: 24114144 Free PMC article.
Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein.
Torres N, Regge MV, Secchiari F, Friedrich AD, Spallanzani RG, Raffo Iraolagoitia XL, Núñez SY, Sierra JM, Ziblat A, Santilli MC, Gilio N, Almada E, Lauche C, Pardo R, Domaica CI, Fuertes MB, Madauss KP, Hance KW, Gloger IS, Zylberman V, Goldbaum FA, Zwirner NW. Torres N, et al. Among authors: spallanzani rg. J Immunother Cancer. 2020 Jun;8(1):e000233. doi: 10.1136/jitc-2019-000233. Epub 2020 Jun 8. J Immunother Cancer. 2020. PMID: 32518090 Free PMC article.
Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC.
Güttlein LN, Benedetti LG, Fresno C, Spallanzani RG, Mansilla SF, Rotondaro C, Raffo Iraolagoitia XL, Salvatierra E, Bravo AI, Fernández EA, Gottifredi V, Zwirner NW, Llera AS, Podhajcer OL. Güttlein LN, et al. Among authors: spallanzani rg. Mol Cancer Res. 2017 Mar;15(3):304-316. doi: 10.1158/1541-7786.MCR-16-0243-T. Epub 2016 Dec 28. Mol Cancer Res. 2017. PMID: 28031408
25 results